PO
$138.77
+4.84
(+3.61%)
As of Oct 15, 2026, 10:15 PM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Aug 6, 2026, the first target we tracked for PODD.
Insulet Corporation (PODD) is trading up at $138.77 (+3.61%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on PODD
Current price targets from 2 firms average $185, ranging from $180 to $190 — 33% above the current $139. Each is tracked to its date and scored the same way a member's call is.
- Jefferies $135 → $190 by Oct 2027 Oct 12, 2026 via Investing.com · Jefferies's track record
- Raymond James $139 → $180 by Aug 2027 Aug 6, 2026 via Investing.com · Raymond James's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Insulet Corporation revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $367.0M | $463.8M | $563.8M | $738.2M | $904.4M | $1.10B | $1.31B | $1.70B | $2.07B | $2.71B |
| Growth (year over year) | +39.1% | +26.4% | +21.6% | +30.9% | +22.5% | +21.5% | +18.8% | +30.0% | +22.1% | +30.7% |
| Gross profit | $211.1M | $277.2M | $370.2M | $480.3M | $582.3M | $752.1M | $805.6M | $1.16B | $1.45B | $1.94B |
| Gross margin | 57.5% | 59.8% | 65.7% | 65.1% | 64.4% | 68.4% | 61.7% | 68.3% | 69.8% | 71.6% |
| Operating income | −$10.7M | −$7.40M | $27.4M | $50.0M | $51.5M | $126.0M | $37.6M | $220.1M | $308.9M | $473.8M |
| Operating margin | −2.9% | −1.6% | 4.9% | 6.8% | 5.7% | 11.5% | 2.9% | 13.0% | 14.9% | 17.5% |
| Net income | −$28.9M | −$26.8M | $3.30M | $11.6M | $6.80M | $16.8M | $4.60M | $206.3M | $418.3M | $247.1M |
| Net margin | −7.9% | −5.8% | 0.6% | 1.6% | 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% |
| EPS (diluted) | −$0.48 | −$0.46 | $0.05 | $0.19 | $0.10 | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 |
| Balance sheet | ||||||||||
| Cash and equivalents | $137.2M | $272.6M | $113.9M | $213.7M | $907.2M | $806.4M | $689.8M | $704.2M | $953.4M | $716.1M |
| Total assets | $456.6M | $840.0M | $928.7M | $1.14B | $1.87B | $2.05B | $2.25B | $2.59B | $3.09B | $3.19B |
| Total liabilities | $393.5M | $661.1M | $716.6M | $1.07B | $1.27B | $1.49B | $1.77B | $1.86B | $1.88B | $1.68B |
| Long-term debt | $332.8M | $566.2M | $592.0M | $887.9M | $1.04B | $1.25B | $1.37B | $1.37B | $1.30B | $930.8M |
| Shareholders' equity | $63.1M | $158.5M | $212.1M | $75.9M | $603.6M | $556.3M | $476.4M | $732.7M | $1.21B | $1.52B |
| Cash flow | ||||||||||
| Operating cash flow | $15.9M | $41.3M | $35.9M | $98.4M | $84.0M | −$68.1M | $119.0M | $145.7M | $430.2M | $569.3M |
| Capital expenditure | $22.1M | $73.8M | $157.4M | $163.7M | $129.0M | $111.9M | $122.9M | $75.6M | $124.9M | $191.6M |
| Free cash flow | −$6.20M | −$32.5M | −$121.5M | −$65.3M | −$45.0M | −$180.0M | −$3.90M | $70.1M | $305.3M | $377.7M |
| Share buybacks | — | — | — | — | — | — | — | $0 | $0 | $59.6M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $543.9M | $597.5M | $569.0M | $649.1M | $706.3M | $783.7M | $761.7M | $801.7M |
| Growth (year over year) | +25.7% | +17.2% | +28.8% | +32.9% | +29.9% | +31.2% | +33.9% | +23.5% |
| Gross profit | $377.1M | $430.9M | $409.0M | $452.2M | $510.1M | $568.6M | $529.1M | $562.6M |
| Gross margin | 69.3% | 72.1% | 71.9% | 69.7% | 72.2% | 72.6% | 69.5% | 70.2% |
| Operating income | $88.1M | $109.4M | $88.8M | $121.1M | $117.7M | $146.2M | $122.1M | $129.7M |
| Operating margin | 16.2% | 18.3% | 15.6% | 18.7% | 16.7% | 18.7% | 16.0% | 16.2% |
| Net income | $77.5M | $100.7M | $35.4M | $22.5M | $87.6M | $101.6M | $91.1M | $95.0M |
| Net margin | 14.2% | 16.9% | 6.2% | 3.5% | 12.4% | 13.0% | 12.0% | 11.8% |
| EPS (diluted) | $1.08 | $1.38 | $0.50 | $0.32 | $1.24 | $1.42 | $1.30 | $1.37 |
| Balance sheet | ||||||||
| Cash and equivalents | $902.6M | $953.4M | $1.28B | $1.12B | $757.4M | $716.1M | $480.4M | $534.9M |
| Total assets | $3.03B | $3.09B | $3.52B | $3.47B | $3.03B | $3.19B | $2.99B | $3.17B |
| Total liabilities | $1.91B | $1.88B | $2.19B | $2.01B | $1.65B | $1.68B | $1.68B | $1.74B |
| Long-term debt | $1.36B | $1.30B | $1.61B | $939.0M | $934.9M | $930.8M | $929.5M | $929.5M |
| Shareholders' equity | $1.12B | $1.21B | $1.33B | $1.46B | $1.38B | $1.52B | $1.30B | $1.42B |
| Cash flow | ||||||||
| Operating cash flow | $108.3M | $147.5M | $63.8M | $196.5M | $125.7M | $183.3M | $113.8M | $88.4M |
| Capital expenditure | $26.7M | $53.6M | $12.3M | $18.6M | $25.6M | $135.1M | $24.3M | $32.5M |
| Free cash flow | $81.6M | $93.9M | $51.5M | $177.9M | $100.1M | $48.2M | $89.5M | $55.9M |
| Share buybacks | $0 | $0 | $0 | $30.1M | $29.5M | $0 | $300.0M | $0 |
From Insulet Corporation's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Insulet Corporation
- Headquarters
- Acton, Massachusetts From SEC filings, Oct 2026
Recent News (20)
-
Jefferies cuts Insulet stock price target on competition concerns
Jefferies cuts Insulet stock price target on competition concerns
-
Why is Insulet stock sliding today?
Why is Insulet stock sliding today?
-
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
-
Artisan Sold Insulet (PODD) Due to Competition Concerns
Artisan Sold Insulet (PODD) Due to Competition Concerns
-
Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Insulet Corporation ("Insulet" or "the Company") (NASDAQ: PODD) for violations of §§10(…
-
Insulet Corporation Investor Alert: Contact SBS by August 31, 2026 for Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation ("Insulet…
-
Insulet Deadline: PODD Investors with Losses in Excess of $100K Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit NEW YORK, Aug. 28, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, …
-
-
-
-
-
-
PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact Levi & Korsinsky Confidence in Insulet's Manufacturing Story Collapsed After Two Omnipod Recalls Exposed Quality Failures Resulting in Analysts Questioning the Scope of Insulet's Manufacturing and Quality-Control Issu…
-
Insulet Corporation (PODD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Insulet Cor…
-
Is Wall Street Bullish or Bearish on Insulet Stock?
Is Wall Street Bullish or Bearish on Insulet Stock?
-
-
Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?
Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?
-
-
Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD LOS ANGELES, Aug. 24, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Insulet Corporation ("Insulet" or "the Company") (NASDAQ: PODD) for violations of §§10(…
-
More Health Care stocks
- MRK Merck & Co.
- MRNA Moderna
- MTD Mettler Toledo
- PFE Pfizer
- REGN Regeneron Pharmaceuticals
- RMD ResMed
- RVTY Revvity
- SOLV Solventum